Skip to main content
OpenTrials

Clinical trial condition

Metastatic Urothelial Cancer

Explore clinical trials studying Metastatic Urothelial Cancer. Study availability and eligibility vary by location and protocol.

16 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Urothelial Cancer trial results

Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973

Conditions
Metastatic Urothelial Cancer
Locations
  • The University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Rocky Mountain Cancer Centers Littleton, Colorado, United States
View all 135 locations
View Trial Details
Completed

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

NCT04995419

Conditions
Metastatic Urothelial Cancer
Locations
  • Site CN86001 Beijing, China
  • Site CN86009 Changsha, China
  • Site CN86002 Guangzhou, China
  • Site CN86006 Hangzhou, China
View Trial Details
Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

NCT03451331

Conditions
Metastatic Urothelial Cancer
Locations
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • John Theuer Cancer Center Hackensack, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
  • Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center New York, United States
View Trial Details
Completed

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718

Conditions
Metastatic Urothelial Cancer
Locations
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Karmanos Cancer Center (Wyane State University) Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details

Related conditions